GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tebapivat   Click here for help

GtoPdb Ligand ID: 13106

Synonyms: AG-946 | AG946 | compound 27 [PMID: 38109501]
PDB Ligand
Compound class: Synthetic organic
Comment: Tebapivat (AG-946) is a small molecule activator of pyruvate kinase (PK) [2]. It acts allosterically, at wild type PK and at physiologically relevent PK isoforms (e.g. PK-R that's expressed in red blood cells). It is intended to increase PK function in red blood cells with defective glycolysis, as observed in diseases such as myelodysplastic syndromes and sickle cell anaemia [3-4].

tebapivat is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 136.34
Molecular weight 392.44
XLogP 0.32
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN1C2=C(C=NN(CC3=CC=CC(=N3)N)C2=O)C4=C1N=C(CC5=NNC=C5)S4
Isomeric SMILES N1N=C(C=C1)CC=2SC3=C(N(C=4C(N(N=CC43)CC5=NC(=CC=C5)N)=O)C)N2
InChI InChI=1S/C18H16N8OS/c1-25-15-12(16-17(25)23-14(28-16)7-10-5-6-20-24-10)8-21-26(18(15)27)9-11-3-2-4-13(19)22-11/h2-6,8H,7,9H2,1H3,(H2,19,22)(H,20,24)
InChI Key DIUOELXIXSCFCR-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Tebapivat (AG-946) was advanced to clinical trial as an investigational PK/PKR allosteric activator. The FDA granted orphan designation in February 2026, for the treatment of sickle cell disease [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04536792 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease Phase 1 Interventional Agios Pharmaceuticals, Inc.
NCT05490446 A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) Phase 2 Interventional Agios Pharmaceuticals, Inc.
NCT06924970 A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) Phase 2 Interventional Agios Pharmaceuticals, Inc.